QS Research · Michael Burry's Scion Capital analyst template · 2006
AMETEK INC/ (AME)
As of 2026-11-20 · 12/15 boxes filled from SEC filings and market data
Report price $222.90 (close 2026-11-20)
Conclusion: PASS
Conviction low · base case -3% · downside -26% · upside +20%
The market is paying for a post-deal AMETEK at 31.3x TTM earnings and 22.3x EV/EBITDA, while the reverse DCF requires +7.0% revenue growth a year for 10 years against +6.6% in FY2025. The record operating performance is visible, but the price already discounts steady delivery, so the balanced setup supports the call. The downside case is -26.3% to $164.21, from -10.0% earnings at a compressed P/E of 25.65x (today 31.3x). The base case is -3.2% to $215.78, from P/E at 30.3x, the peer median P/E. The upside case is +20.1% to $267.70, from +20.1% earnings at today's P/E of 31.3x. The range is wide enough to keep conviction low: the base offers little cushion, the downside is a real earnings-compression outcome, and the upside needs the current multiple to hold on higher earnings. With delivery and Indicor integration as the proof points, PASS is the call.
Key numbers
- Share price: $222.90
- Market cap: $51.11B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $8.19B
- EV / EBITDA (TTM): 22.3x
- P/E (TTM): 31.3x
- FCF yield: 3.8%
- Price / book: 4.37x
- EV / FCF (TTM): 29.6x
- Revenue growth (latest fiscal year): +6.6%
- ROIC (TTM): 9.8%
- WACC: 7.8%
- Economic profit spread: +2.0 pts
The 15 boxes
- ✓ 1. Long-form business notes
AMETEK, whose predecessor was incorporated in 1930 as American Machine and Metals, makes money through two niche manufacturing groups: EIG (advanced analytical, test and measurement instruments; 70% process/analytical and 30% aerospace/power of EIG FY2025 net sales) and EMG (precision motion control, medical components/devices, thermal management, specialty metals and interconnects; 70% automation/engineered and 30% aerospace of EMG FY2025 net sales). FY2025 sales were $7,401.1M, up 6.6%, with operating income $1.91B and net income $1.48B; TTM to 2026-09-30 revenue was $8.19B and operating income $2.13B. Between the FY2020 and FY2025 reports the company used acquisitions (15 deals since 2021, ~$1.8B annualized sales) and shifted its Growth Model target to high single digit sales growth, while EIG's process/analytical mix fell to 70% from 73% and EMG's description added medical components/devices.
- ✓ 2. Competitive advantage
AMETEK's advantage is visible mainly in the numbers, not in the language: operating margin held at roughly 24-26% of revenue across FY2022-FY2025 and the TTM to 2026-09-30 (about 26.0% TTM), with capex only about 1.8% of revenue and operating cash flow about 1.28x net income in the TTM. The 10-K describes the markets as "highly competitive" on technology, performance, quality, service and price, with "numerous companies" competing in each process and analytical instrument market, no single patent or trademark deemed essential, and no competitors named or market shares quantified. Returns on book equity are only about 14% (TTM net income $1.63B over $11.70B equity), and the 10-K itself flags cyclical served markets and rivals with greater resources, so the record reads as a strong-margin niche franchise rather than a moat the filings document.
- ✓ 3. 10-Q takeaways
Q3 2026 was a record quarter: sales $2.22B (+17% y/y), GAAP operating income $584.9M and GAAP diluted EPS $1.85, with adjusted EPS $2.21 (+17%) after adding back $0.36 of acquisition amortization and deal costs. Adjusted operating margin rose 60bp to 26.8% and core margins expanded 110bp, while quarter operating cash flow grew 27% to $560.6M at 124% free-cash-flow conversion. The company raised FY2026 adjusted EPS guidance to $8.53-$8.57 from $8.20-$8.30 on mid-teens sales growth, and guided Q4 adjusted EPS to $2.26-$2.30. The quarter's balance sheet is transformed by $5,345.8M of acquisition cash paid (Indicor in August 2026), funded with $4.0B of term loans, and buybacks fell to near zero versus $150.5M in Q3 2025.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.